<DOC>
	<DOCNO>NCT02468570</DOCNO>
	<brief_summary>Phase 3 substudy enrol approximately 100 subject , age ≥ 18 ≤ 70 year old , PKU concurrently participate 165-302 study .</brief_summary>
	<brief_title>A Phase 3 Substudy Evaluate Executive Function Adults With PKU Who Are Participating Phase 3 Study , 165-302</brief_title>
	<detailed_description>This Phase 3 substudy enrol approximately 100 subject , age ≥ 18 ≤ 70 year old , PKU concurrently treat BMN 165 placebo Part 2 BMN 165 Part 4 Study 165-302 . No study drug administer part study . For study , subject ask perform computer-based assessment ( CANTAB ) ass executive function ( specifically , attention , work memory , cognitive flexibility ) answer question current state self perception ( subject global assessment comprise seven question ) . The study visit follow : screening , baseline visit , 3 additional study visit different time point study .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>Are currently participate Part 1 Study 165302 meet criterion participation Part 2 165302 Are willing able provide write , sign informed consent nature study explain prior researchrelated procedure . Have ability complete CANTAB subject global assessment . Are willing able comply study procedure . Any condition , view investigator , place subject high risk poor compliance terminate early study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PKU</keyword>
	<keyword>PEG-PAL</keyword>
	<keyword>Pegvaliase</keyword>
	<keyword>BMN 165</keyword>
	<keyword>rAv-PAL PEG</keyword>
	<keyword>PRISM 302</keyword>
	<keyword>PRISM 303</keyword>
	<keyword>BioMarin</keyword>
	<keyword>165-302</keyword>
</DOC>